The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Survival outcomes and access to novel therapies in patients with AML and low socioeconomic status
In this video, Maria Amaya, MD, PhD, University of Colorado Anschutz Medical School, Aurora, CO, briefly discusses an analysis of real-world data, which aimed to investigate the outcomes of patients with acute myeloid leukemia (AML) based on socioeconomic status (SES). The findings show that patients with lower SES have more limited access to novel therapies and poorer survival outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, so for this study we utilize the Flatiron data. So they have basically data across the US from AML patients. They have about 10,000 patients within their cohort and it’s a real-world study, so it involves community centers and academic centers and it has excellent survival data. So we basically took all the AML cohort. We ended up with about 3,000 patients in our study and we looked back to see what their outcomes were based on socioeconomic status...
Yeah, so for this study we utilize the Flatiron data. So they have basically data across the US from AML patients. They have about 10,000 patients within their cohort and it’s a real-world study, so it involves community centers and academic centers and it has excellent survival data. So we basically took all the AML cohort. We ended up with about 3,000 patients in our study and we looked back to see what their outcomes were based on socioeconomic status.
So what we found was that lower socioeconomic status patients have worse survival and when you look down at what kind of therapies they got, they’re treated differently. So basically the lower SES or lower socioeconomic status patients are treated more with induction chemotherapy, they are enrolled less in clinical trials, and they receive less novel therapies such as venetoclax or FLT3 inhibitors. And so we are concerned that some of our lower socioeconomic status patients don’t have access to novel therapies and that is impacting their care and their survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb: Honoraria.
